Search results for "BIOTIC"

showing 10 items of 1505 documents

Complex Regulatory Networks Governing Production of the Glycopeptide A40926

2018

Glycopeptides (GPAs) are an important class of antibiotics, with vancomycin and teicoplanin being used in the last 40 years as drugs of last resort to treat infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. A few new GPAs have since reached the market. One of them is dalbavancin, a derivative of A40926 produced by the actinomycete Nonomuraea sp. ATCC 39727, recently classified as N. gerenzanensis. This review summarizes what we currently know on the multilevel regulatory processes governing production of the glycopeptide A40926 and the different approaches used to increase antibiotic yields. Some nutrients, e.g., valine, l-glutamine and mal…

0301 basic medicineMicrobiology (medical)medicine.drug_class030106 microbiologyAntibioticsInfectious DiseaseReviewGlycopeptide antibioticBiologyLuxR solomedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesStrRValinemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsA40926Regulatory geneRegulator geneTeicoplaninlcsh:RM1-950DalbavancinLALA40926; Dalbavancin; Dbv cluster; Glycopeptide antibiotics; LAL; LuxR solo; Regulatory genes; StrR; Microbiology; Biochemistry; Pharmacology Toxicology and Pharmaceutics (all); Microbiology (medical); Infectious Diseases; Pharmacology (medical)regulatory genesGlycopeptidelcsh:Therapeutics. PharmacologyInfectious DiseasesDalbavancinStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Dbv clusterVancomycinglycopeptide antibioticsmedicine.drugAntibiotics
researchProduct

2021

The gut brain axis seems to modulate various psychiatric and neurological disorders such as Alzheimer’s disease (AD). Growing evidence has led to the assumption that the gut microbiome might contribute to or even present the nucleus of origin for these diseases. In this regard, modifiers of the microbial composition might provide attractive new therapeutics. Aim of our study was to elucidate the effect of a rigorously changed gut microbiome on pathological hallmarks of AD. 5xFAD model mice were treated by antibiotics or probiotics (L. acidophilus and L. rhamnosus) for 14 weeks. Pathogenesis was measured by nest building capability and plaque deposition. The gut microbiome was affected as ex…

0301 basic medicineMicrobiology (medical)medicine.drug_classAntibioticsGut–brain axisBlood sugarDiseaseBiologymedicine.diseaseMicrobiologyPathogenesis03 medical and health sciences030104 developmental biology0302 clinical medicineGlycationVirologyDiabetes mellitusImmunologymedicineReceptor030217 neurology & neurosurgeryMicroorganisms
researchProduct

2021

Over the past few decades, extensively drug resistant (XDR) resistant Klebsiella pneumoniae has become a notable burden to healthcare all over the world. Especially carbapenemase-producing strains are problematic due to their capability to withstand even last resort antibiotics. Some sequence types (STs) of K. pneumoniae are significantly more prevalent in hospital settings in comparison to other equally resistant strains. This provokes the question whether or not there are phenotypic characteristics that may render certain K. pneumoniae more suitable for epidemic dispersal between patients, hospitals, and different environments. In this study, we selected seven epidemic and non-epidemic ca…

0301 basic medicineMicrobiology (medical)medicine.drug_classKlebsiella pneumoniae030106 microbiologyImmunologyAntibioticsDrought toleranceVirulenceDrug resistanceBiologyAntimicrobialbiology.organism_classificationMicrobiologyMicrobiology03 medical and health sciences030104 developmental biologyInfectious DiseasesAntibiotic resistanceGenotypemedicineFrontiers in Cellular and Infection Microbiology
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct

Topic Application of the Probiotic Streptococcus dentisani Improves Clinical and Microbiological Parameters Associated With Oral Health

2020

Streptococcus dentisani 7746, isolated from dental plaque of caries-free individuals, has been shown to have several beneficial effects in vitro which could contribute to promote oral health, including an antimicrobial activity against oral pathogens by the production of bacteriocins and a pH buffering capacity through ammonia production. Previous work has shown that S. dentisani was able to colonize the oral cavity for 2–4 weeks after application. The aim of the present work was to evaluate its clinical efficacy by a randomized, double-blind, placebo-controlled parallel group study. Fifty nine volunteers were enrolled in the study and randomly assigned to a treatment or placebo group. The …

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySalivadental plaque030106 microbiologyImmunologylcsh:QR1-502Oral HealthDental CariesOral healthPlaceboDental plaqueMicrobiologyGastroenterologyPlacebo grouplcsh:Microbiologylaw.inventionStreptococcus mutans03 medical and health sciencesProbioticCellular and Infection MicrobiologybacteriocinlawInternal medicinemedicineHumansSalivasalivary flowOriginal Researchbusiness.industryProbioticsStreptococcusAntimicrobialmedicine.disease030104 developmental biologyInfectious DiseasesbusinessprobioticStreptococcus dentisaniFrontiers in Cellular and Infection Microbiology
researchProduct

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

2018

[Background]: While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)–infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear.

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySynbioticsCD4 T cellsPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAcquired immunodeficiency syndrome (AIDS)lawInternal medicinemedicineImmunoactivation030212 general & internal medicineYoung adultAdverse effectInflammationbusiness.industrySurrogate endpointMicrobiotaProbioticsvirus diseasesmedicine.diseaseClinical trial030104 developmental biologyInfectious DiseasesbusinessClinical Infectious Diseases
researchProduct

Identification of virulence factors and antibiotic resistance markers using bacterial genomics.

2016

International audience; In recent years, the number of multidrug-resistant bacteria has increased rapidly and several epidemics were signaled in different regions of the world. Faced with this situation that presents a major global public health concern, the development and the use of new and rapid technologies is more than urgent. The use of the next-generation sequencing platforms by microbiologists and infectious disease specialists has allowed great progress in the medical field. Here, we review the usefulness of whole-genome sequencing for the detection of virulence and antibiotic resistance associated genes.

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyVirulence Factors[SDV]Life Sciences [q-bio]030106 microbiologyVirulenceComputational biologyBiologyMicrobiology03 medical and health sciencesAntibiotic resistanceDrug Resistance Multiple BacterialmedicineHumansWhole genome sequencingBacteriaVirulence[ SDV ] Life Sciences [q-bio]business.industryBacterial genomicsPublic healthHigh-Throughput Nucleotide SequencingGenomicsbiology.organism_classification3. Good healthBiotechnology[SDV] Life Sciences [q-bio]Infectious disease (medical specialty)Spectrometry Mass Matrix-Assisted Laser Desorption-IonizationbusinessGenome BacterialBacteria
researchProduct

Selection of New Probiotics for Endometrial Health

2019

Microbiota is a crucial player in gynecologic health, in which bacteria can shift to a dysbiotic state triggering a pathogenic process. Based on an ecological understanding of the problem, the aim of this study is to select a potential probiotic strain to improve female reproductive tract based on its capacity to initially lower pH and to promote the reduction of pathogenic bacteria. Based on this rationale, strain Lactobacillus rhamnosus BPL005 was initially selected for its capacity to reduce in vitro pH levels and produce organic acids. Subsequently, strain L. rhamnosus BPL005 (CECT 8800) was demonstrated to have a protective role on endometrial infections in an in vitro model of bacteri…

0301 basic medicineMicrobiology (medical)pathogen inhibition030106 microbiologyImmunologyCarboxylic Acidslcsh:QR1-502Atopobium vaginaemedicine.disease_causeReproductive Tract InfectionsMicrobiologylcsh:MicrobiologyStreptococcus agalactiaeMicrobiologylaw.invention03 medical and health sciencesPropionibacterium acnesProbioticLactobacillus rhamnosuslawAntibiosismedicineHumansGardnerella vaginalisendometrial healthPropionibacterium acnesL. rhamnosus BPL005 (CECT 8800)Cells CulturedbiologyLacticaseibacillus rhamnosusMicrobiotaProbioticsfood and beveragesEpithelial CellsPathogenic bacteriaGenitalia FemaleHydrogen-Ion Concentrationbiology.organism_classificationGardnerella vaginalisActinobacteria030104 developmental biologyInfectious DiseasesStreptococcus agalactiaegynecological pathogensFemaleBacteriaprobioticFrontiers in Cellular and Infection Microbiology
researchProduct

Phage Therapy in Livestock and Companion Animals

2021

The irrational use of antibiotics has led to a high emergence of multi-drug resistant (MDR) bacteria. The traditional overuse of antibiotics in the animal feed industry plays a crucial role in the emergence of these pathogens that pose both economic and health problems. In addition, antibiotics have also recently experienced an increase to treat companion animal infections, promoting the emergence of MDR bacteria in pets, which can reach humans. Phages have been proposed as an alternative for antibiotics for the treatment of livestock and companion animal infections due to their multiple advantages as adaptative drugs, such as their ability to evolve, to multiply at the site of infections, …

0301 basic medicineMicrobiology (medical)phage therapyPhage therapyCoronavirus disease 2019 (COVID-19)Phage therapymedicine.drug_classAnimal feedVeterinary medicineCompanion animalmedicine.medical_treatment030106 microbiologyAntibioticsRM1-950ReviewBiologyAntimicrobial resistanceBiochemistryMicrobiologyantibiotics03 medical and health sciencesHealth problemsAntibiotic resistanceAntibioticsmedicinePharmacology (medical)antimicrobial resistanceGeneral Pharmacology Toxicology and Pharmaceuticsbusiness.industryBiotechnologyveterinary medicine030104 developmental biologyInfectious DiseasesLivestockTherapeutics. PharmacologybusinessAntibiotics
researchProduct

Directed evolution of a Mycobacteriophage

2019

This article belongs to the Special Issue Bacteriophages: Alternatives to Antibiotics and Beyond.

0301 basic medicineMicrobiology (medical)phage therapyPhage therapyPhage therapyMycobacteriophagemedicine.medical_treatment030106 microbiologymycobacteriophagesMycobacterium smegmatismedicine.disease_causeBiochemistryMicrobiologyArticle03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsdirected evolutionGeneticsMycobacteriophagesbiologyMycobacterium smegmatislcsh:RM1-950Pathogenic bacteriaMycobacteriophagesbiology.organism_classificationDirected evolution3. Good health030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. PharmacologyLytic cycle<i>Mycobacterium smegmatis</i>Directed evolution
researchProduct